<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28490337</article-id><article-id pub-id-type="pmc">5426055</article-id><article-id pub-id-type="publisher-id">546</article-id><article-id pub-id-type="doi">10.1186/s12933-017-0546-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3741-5560</contrib-id><name><surname>Yamada</surname><given-names>Hirotsugu</given-names></name><address><phone>81-88-633-9311</phone><email>yamadah@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tanaka</surname><given-names>Atsushi</given-names></name><address><email>tanakaa2@cc.saga-u.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kusunose</surname><given-names>Kenya</given-names></name><address><email>kusunosek@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Amano</surname><given-names>Rie</given-names></name><address><email>amano.rie@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsuhisa</surname><given-names>Munehide</given-names></name><address><email>matuhisa@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Daida</surname><given-names>Hiroyuki</given-names></name><address><email>daida@juntendo.ac.jp</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>Masaaki</given-names></name><address><email>mitoka@clin.medic.mie-u.ac.jp</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tsutsui</surname><given-names>Hiroyuki</given-names></name><address><email>htsutsui@cardiol.med.kyushu-u.ac.jp</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Nanasato</surname><given-names>Mamoru</given-names></name><address><email>nana@nagoya2.jrc.or.jp</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kamiya</surname><given-names>Haruo</given-names></name><address><email>ha.kamiya@nifty.ne.jp</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bando</surname><given-names>Yasuko K.</given-names></name><address><email>ybando@med.nagoya-u.ac.jp</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Odawara</surname><given-names>Masato</given-names></name><address><email>odawara@tokyo-med.ac.jp</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Yoshida</surname><given-names>Hisako</given-names></name><address><email>hyoshida@cc.saga-u.ac.jp</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Murohara</surname><given-names>Toyoaki</given-names></name><address><email>murohara@med.nagoya-u.ac.jp</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Sata</surname><given-names>Masataka</given-names></name><address><email>masataka.sata@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Node</surname><given-names>Koichi</given-names></name><address><phone>81-952-34-2364</phone><email>node@cc.saga-u.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><collab>for the PROLOGUE Study Investigators</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 2191</institution-id><institution-id institution-id-type="GRID">grid.412772.5</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>Tokushima University Hospital, </institution></institution-wrap>2-50-1 Kuramoto, Tokushima, Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1172 4459</institution-id><institution-id institution-id-type="GRID">grid.412339.e</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>Saga University, </institution></institution-wrap>5-5-1 Nabeshima, Saga, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1092 3579</institution-id><institution-id institution-id-type="GRID">grid.267335.6</institution-id><institution>Department of Diabetes Therapeutics and Research Center, </institution><institution>Tokushima University, </institution></institution-wrap>Tokushima, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1762 2738</institution-id><institution-id institution-id-type="GRID">grid.258269.2</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>Juntendo University Graduate School of Medicine, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 555X</institution-id><institution-id institution-id-type="GRID">grid.260026.0</institution-id><institution>Department of Cardiology and Nephrology, </institution><institution>Mie University Graduate School of Medicine, </institution></institution-wrap>Tsu, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2242 4849</institution-id><institution-id institution-id-type="GRID">grid.177174.3</institution-id><institution>Department of Cardiovascular Medicine, Faculty of Medical Sciences, </institution><institution>Kyushu University, </institution></institution-wrap>Fukuoka, Japan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.413410.3</institution-id><institution>Cardiovascular Center, </institution><institution>Japanese Red Cross Nagoya Daini Hospital, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 818X</institution-id><institution-id institution-id-type="GRID">grid.414932.9</institution-id><institution>Division of Cardiology, </institution><institution>Japanese Red Cross Nagoya Daiichi Hospital, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution>Department of Cardiology, </institution><institution>Nagoya University Graduate School of Medicine, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0663 3325</institution-id><institution-id institution-id-type="GRID">grid.410793.8</institution-id><institution>Department of Diabetes, Endocrinology, Metabolism and Rheumatology, </institution><institution>Tokyo Medical University, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1172 4459</institution-id><institution-id institution-id-type="GRID">grid.412339.e</institution-id><institution>Clinical Research Center, </institution><institution>Saga University, </institution></institution-wrap>Saga, Japan </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><elocation-id>63</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>4</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Diabetes is associated closely with an increased risk of cardiovascular events, including diastolic dysfunction and heart failure that leads to a shortening of life expectancy. It is therefore extremely valuable to evaluate the impact of antidiabetic agents on cardiac function. However, the influence of dipeptidyl peptidase 4 inhibitors on cardiac function is controversial and a major matter of clinical concern. We therefore evaluated the effect of sitagliptin on echocardiographic parameters of diastolic function in patients with type 2 diabetes as a sub-analysis of the PROLOGUE study.</p></sec><sec><title>Methods</title><p>Patients in the PROLOGUE study were assigned randomly to either add-on sitagliptin treatment or conventional antidiabetic treatment. Of the 463 patients in the overall study, 115 patients (55 in the sitagliptin group and 60 in the conventional group) who had complete echocardiographic data of the ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e&#x02032;) at baseline and after 12 and 24&#x000a0;months were included in this study. The primary endpoint of this post hoc sub-analysis was a comparison of the changes in the ratio of E to e&#x02032; (E/e&#x02032;) between the two groups from baseline to 24&#x000a0;months.</p></sec><sec><title>Results</title><p>The baseline-adjusted change in E/e&#x02032; during 24&#x000a0;months was significantly lower in the sitagliptin group than in the conventional group (&#x02212;0.18&#x000a0;&#x000b1;&#x000a0;0.55 vs. 1.91&#x000a0;&#x000b1;&#x000a0;0.53, p&#x000a0;=&#x000a0;0.008), irrespective of a higher E/e&#x02032; value at baseline in the sitagliptin group. In analysis of covariance, sitagliptin treatment was significantly associated with change in E/e&#x02032; over 24&#x000a0;months (&#x003b2;&#x000a0;=&#x000a0;&#x02212;9.959, p&#x000a0;=&#x000a0;0.001), independent of other clinical variables at baseline such as blood pressure, HbA1c, and medications for diabetes. Changes in other clinical variables including blood pressure and glycemic parameters, and echocardiographic parameters, such as cardiac structure and systolic function, were comparable between the two groups. There was also no significant difference in the serum levels of N-terminal-pro brain natriuretic peptide and high-sensitive C-reactive protein between the two groups during the study period.</p></sec><sec><title>Conclusions</title><p>Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24&#x000a0;months attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e&#x02032;) independent of other clinical variables such as blood pressure and glycemic control.</p><p>
<italic>Trial registration</italic> UMIN000004490 (University Hospital Medical Information Network Clinical Trials). <ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005356">https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005356</ext-link>; registered November 1, 2010</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12933-017-0546-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Sitagliptin</kwd><kwd>T2DM</kwd><kwd>Echocardiography</kwd><kwd>Diastolic function</kwd><kwd>NT-proBNP</kwd></kwd-group><funding-group><award-group><funding-source><institution>Clinical Research Promotion Foundation</institution></funding-source><award-id>No.1026</award-id><principal-award-recipient><name><surname>Node</surname><given-names>Koichi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Type 2 diabetes mellitus (T2DM) is associated closely with an increased risk of cardiovascular (CV) events including heart failure [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The prevalence of patients who develop heart failure is greater in diabetic individuals than in non-diabetic individuals, and diabetes is known to be a strong risk factor for the development of heart failure [<xref ref-type="bibr" rid="CR3">3</xref>]. It has been shown that once individuals with T2DM developed heart failure their 5-year survival rate was 12.5%, a rate considerably lower than in individuals without heart failure [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, diabetes contributes to a worse outcome in patients with left ventricular (LV) diastolic dysfunction than those with systolic dysfunction [<xref ref-type="bibr" rid="CR5">5</xref>]. However, intensive glucose-lowering therapy with antidiabetic agents does not always reduce the risk of heart failure [<xref ref-type="bibr" rid="CR6">6</xref>], with some agents having unfavorable clinical effects on heart failure [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, it is important to evaluate the impact of antidiabetic agents on cardiac function [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p>To date, three randomized controlled trials that focused on major CV outcomes in patients with T2DM treated with either dipeptidyl peptidase-4 (DPP-4) inhibitors or placebo have been reported. Alogliptin in the EXAMIN [<xref ref-type="bibr" rid="CR11">11</xref>], saxagliptin in the SAVOR-TIMI 53 [<xref ref-type="bibr" rid="CR12">12</xref>], and sitagliptin in the TECOS [<xref ref-type="bibr" rid="CR13">13</xref>] all showed non-inferior to placebo to lower the risk of the composite primary endpoint of CV death, myocardial infarction or ischemic stroke. However, in the SAVOR-TIMI 53 trial a 27% increase in the rate of hospital admission for heart failure was found in the group with saxagliptin [<xref ref-type="bibr" rid="CR14">14</xref>]. Results from meta-analyses of randomized trials also demonstrated that DPP-4 inhibitors were associated with an increased risk of heart failure [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In contrast, there was no significant difference in the rate of hospital admissions for heart failure between sitagliptin and placebo groups in the TECOS trial. Taken together, these results show the influence of DPP-4 inhibitors on cardiac function is still a major clinical concern.</p><p>The PROLOGUE study (University hospital Medical Information Network Center: ID 000004490) was a prospective multicenter study conducted in Japan to evaluate the inhibitory effect of sitagliptin on the progression of atherosclerosis based on carotid-artery intima-media thickness (IMT) assessed by ultrasonography over a 2-year follow-up period [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In this study, echocardiography at baseline and after 12 and 24&#x000a0;months of treatment was an optional examination. In order to elucidate the effect of DPP-4 inhibitor on cardiac function we carried out a sub-study of the PROLOGUE study that investigated the effect of sitagliptin on two-dimensional and Doppler echocardiographic parameters, mainly focusing on left ventricular diastolic function from baseline to 24&#x000a0;months.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>The details of the PROLOGUE study design have been published elsewhere [<xref ref-type="bibr" rid="CR17">17</xref>]. Briefly, the study was a multicenter, randomized, prospective, open-label, blinded-endpoint trial carried out at 48 institutions in Japan. A total of 463 patients older than 30&#x000a0;years who had T2DM with an HbA1c level of 6.2&#x02013;9.4% despite conventional treatment with diet, exercise, and/or pharmacologic therapy with oral antidiabetic agents (except incretin-related therapy) for more than 3&#x000a0;months were enrolled in the study between June 2011 and September 2012. Patients with severe heart failure with a New York Heart Association (NYHA) functional classification of III and IV were excluded. The inclusion and exclusion criteria for the study have been published previously [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The patients were assigned randomly using a 1:1 ratio to either add-on sitagliptin treatment (sitagliptin group, n&#x000a0;=&#x000a0;232) or conventional glucose-lowering treatment (conventional group, n&#x000a0;=&#x000a0;231). The primary endpoint of the PROLOGUE study was the change in mean common carotid IMT 24&#x000a0;months after treatment randomization. Echocardiography was performed as an ad hoc examination at baseline and 12 and 24&#x000a0;months after treatment randomization. The ethical committees of each participating institution approved the study protocol, with written informed consent for participation in the study being obtained from all the subjects.</p></sec><sec id="Sec4"><title>Study population</title><p>Of the 436 participants in the PROLOGUE study, an echocardiographic examination was performed at baseline in 152 patients in the sitagliptin group and 148 patients in the conventional group. The present study analyzed the data of 115 patients (55 patients in the sitagliptin group and 60 patients in the conventional group) who had echocardiographic data of the ratio of peak early diastolic transmitral flow (TMF) velocity (E) to peak early diastolic mitral annular velocity (e&#x02032;) at baseline and at both 12 and 24&#x000a0;months (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Study participant flow diagram. E/e&#x02032;: ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e&#x02032;)</p></caption><graphic xlink:href="12933_2017_546_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec5"><title>Echocardiographic examination</title><p>Echocardiography was performed in a standard manner using commercially available ultrasound diagnostic machines with various hemodynamic parameters being measured at each institution. The recordings and measurements were performed in accordance with the guidelines issued by the American Society of Echocardiograph [<xref ref-type="bibr" rid="CR19">19</xref>]. TMF velocity was recorded from the apical long-axis or four-chamber view. The ratio of the peak early diastolic (E) and the peak atrial systolic (A) TMF velocities was calculated. The deceleration time&#x000a0;(DT) of early TMF velocity was also measured. The mitral annular motion velocity pattern was recorded from the apical four-chamber view with the sample volume located at the lateral or septal side of the mitral annulus using pulsed tissue Doppler echocardiography. The mean peak early diastolic mitral annular velocity (e&#x02032;) in the septal and lateral side was measured, and the ratio of E to e&#x02032; (E/e&#x02032;) then calculated as a marker of LV filling pressure. In addition to these diastolic parameters, routine echocardiographic parameters were also measured and included LV end-diastolic dimensions (LVDd) and LV end-systolic dimensions (LVDs) measured from M-mode or 2-dimensional echocardiogram of the LV. Fractional shortening was calculated as (LVDs&#x02014;LVds)/LVDdx100. The LV ejection fraction (LVEF) was measured and calculated from the apical two- and four-chamber view using a modified Simpson&#x02019;s method. LV mass was calculated as reported previously [<xref ref-type="bibr" rid="CR20">20</xref>]. Relative wall thickness was calculated as two times posterior wall thickness divided by LVDd [<xref ref-type="bibr" rid="CR21">21</xref>]. All Doppler recordings were performed during an end-expiratory breath hold. The mean values of three consecutive cardiac cycles were used in the analysis. Measurement and interpretation of the echocardiography was performed locally at each institution. The readers were blinded to the patients&#x02019; assignment to treatment.</p></sec><sec id="Sec6"><title>Laboratory examination</title><p>Blood samples were collected at baseline and after 12 and 24&#x000a0;months. The parameters analyzed are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitive CRP were measured in a centralized laboratory (SRL Co. Tokyo, Japan) using an electrochemiluminescence immunoassay (ECLIA) and nephelometry, respectively.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Clinical characteristics between the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="3">Baseline</th><th align="left" colspan="3">24&#x000a0;months</th><th align="left" colspan="3">Least square means of baseline-adjusted changes</th></tr><tr><th align="left">Sitagliptin (n&#x000a0;=&#x000a0;55)</th><th align="left">Conventional (n&#x000a0;=&#x000a0;60)</th><th align="left">p value</th><th align="left">Sitagliptin (n&#x000a0;=&#x000a0;55)</th><th align="left">Conventional (n&#x000a0;=&#x000a0;60)</th><th align="left">p value</th><th align="left">Sitagliptin (n&#x000a0;=&#x000a0;55)</th><th align="left">Conventional (n&#x000a0;=&#x000a0;60)</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">Age, year</td><td align="left">69&#x000a0;&#x000b1;&#x000a0;8</td><td align="left">69&#x000a0;&#x000b1;&#x000a0;9</td><td char="." align="char">0.973</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Gender (male/female)</td><td align="left">38/17</td><td align="left">39/21</td><td char="." align="char">0.641</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Body mass index, kg/m<sup>2</sup>
</td><td align="left">25.9&#x000a0;&#x000b1;&#x000a0;3.3</td><td align="left">24.8&#x000a0;&#x000b1;&#x000a0;3.9</td><td char="." align="char">0.098</td><td align="left">25.5&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="left">24.6&#x000a0;&#x000b1;&#x000a0;3.8</td><td char="." align="char">0.203</td><td char="&#x000b1;" align="char">&#x02212;0.10&#x000a0;&#x000b1;&#x000a0;0.16</td><td char="&#x000b1;" align="char">&#x02212;0.13&#x000a0;&#x000b1;&#x000a0;0.15</td><td char="." align="char">0.368</td></tr><tr><td align="left">Systolic BP, mmHg</td><td align="left">132&#x000a0;&#x000b1;&#x000a0;17</td><td align="left">129&#x000a0;&#x000b1;&#x000a0;19</td><td char="." align="char">0.287</td><td align="left">133&#x000a0;&#x000b1;&#x000a0;16</td><td align="left">130&#x000a0;&#x000b1;&#x000a0;20</td><td char="." align="char">0.377</td><td char="&#x000b1;" align="char">1.70&#x000a0;&#x000b1;&#x000a0;2.20 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">0.34&#x000a0;&#x000b1;&#x000a0;2.09</td><td char="." align="char">0.656</td></tr><tr><td align="left">Diastolic BP, mmHg</td><td align="left">74&#x000a0;&#x000b1;&#x000a0;11</td><td align="left">71&#x000a0;&#x000b1;&#x000a0;12</td><td char="." align="char">0.090</td><td align="left">75&#x000a0;&#x000b1;&#x000a0;13 (n&#x000a0;=&#x000a0;54)</td><td align="left">71&#x000a0;&#x000b1;&#x000a0;11</td><td char="." align="char">0.076</td><td char="&#x000b1;" align="char">1.76&#x000a0;&#x000b1;&#x000a0;1.47 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">&#x02212;0.54&#x000a0;&#x000b1;&#x000a0;1.40</td><td char="." align="char">0.263</td></tr><tr><td align="left">Heart rate, beats/min</td><td align="left">70&#x000a0;&#x000b1;&#x000a0;12</td><td align="left">67&#x000a0;&#x000b1;&#x000a0;12</td><td char="." align="char">0.196</td><td align="left">71&#x000a0;&#x000b1;&#x000a0;16</td><td align="left">67&#x000a0;&#x000b1;&#x000a0;10</td><td char="." align="char">0.129</td><td char="&#x000b1;" align="char">3.37&#x000a0;&#x000b1;&#x000a0;1.49</td><td char="&#x000b1;" align="char">&#x02212;2.14&#x000a0;&#x000b1;&#x000a0;1.43</td><td char="." align="char">0.009</td></tr><tr><td align="left">Total cholesterol, mmol/L</td><td align="left">4.4&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left">4.6&#x000a0;&#x000b1;&#x000a0;0.9</td><td char="." align="char">0.43</td><td align="left">4.4&#x000a0;&#x000b1;&#x000a0;0.8 (n&#x000a0;=&#x000a0;54)</td><td align="left">4.4&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="." align="char">0.690</td><td char="&#x000b1;" align="char">&#x02212;0.08&#x000a0;&#x000b1;&#x000a0;0.09 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">&#x02212;0.10&#x000a0;&#x000b1;&#x000a0;0.08</td><td char="." align="char">0.899</td></tr><tr><td align="left">HDL cholesterol, mmol/L</td><td align="left">1.3&#x000a0;&#x000b1;&#x000a0;0.3 (n&#x000a0;=&#x000a0;55)</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.4 (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.617</td><td align="left">1.3&#x000a0;&#x000b1;&#x000a0;0.3 (n&#x000a0;=&#x000a0;54)</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="." align="char">0.412</td><td char="&#x000b1;" align="char">&#x02212;0.03&#x000a0;&#x000b1;&#x000a0;0.03 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">0.00&#x000a0;&#x000b1;&#x000a0;0.03 (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.362</td></tr><tr><td align="left">Triglycerides, mmol/L</td><td align="left">3.1 [2.2&#x02013;4.5] (n&#x000a0;=&#x000a0;54)</td><td align="left">3.1 [2.3&#x02013;4.2]</td><td char="." align="char">0.536</td><td align="left">2.9 [2.2&#x02013;5.0] (n&#x000a0;=&#x000a0;54)</td><td align="left">2.9 [2.1&#x02013;3.9]</td><td char="." align="char">0.151</td><td char="&#x000b1;" align="char">0.06&#x000a0;&#x000b1;&#x000a0;0.06 (n&#x000a0;=&#x000a0;53)</td><td char="&#x000b1;" align="char">&#x02212;0.08&#x000a0;&#x000b1;&#x000a0;0.05</td><td char="." align="char">0.078</td></tr><tr><td align="left">Creatinine, &#x003bc;mol/L</td><td align="left">71.6 [61.9&#x02013;86.6]</td><td align="left">68.1 [59.2&#x02013;89.3]</td><td char="." align="char">0.496</td><td align="left">75.1 [62.8&#x02013;87.5] (n&#x000a0;=&#x000a0;54)</td><td align="left">69.0 [61.0&#x02013;98.1]</td><td char="." align="char">0.740</td><td char="&#x000b1;" align="char">2.65&#x000a0;&#x000b1;&#x000a0;1.77 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">4.42&#x000a0;&#x000b1;&#x000a0;1.77</td><td char="." align="char">0.345</td></tr><tr><td align="left">eGFR, mL/min/1.73&#x000a0;m<sup>2</sup>
</td><td align="left">66.6&#x000a0;&#x000b1;&#x000a0;15.9</td><td align="left">67.3&#x000a0;&#x000b1;&#x000a0;18.4</td><td char="." align="char">0.834</td><td align="left">65.1&#x000a0;&#x000b1;&#x000a0;14.1 (n&#x000a0;=&#x000a0;54)</td><td align="left">67.1&#x000a0;&#x000b1;&#x000a0;19.7</td><td char="." align="char">0.757</td><td char="&#x000b1;" align="char">&#x02212;1.96&#x000a0;&#x000b1;&#x000a0;1.10 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">&#x02013;3.18&#x000a0;&#x000b1;&#x000a0;1.04</td><td char="." align="char">0.419</td></tr><tr><td align="left">Fasting plasma glucose, mmol/L</td><td align="left">7.5&#x000a0;&#x000b1;&#x000a0;1.8 (n&#x000a0;=&#x000a0;53)</td><td align="left">7.1&#x000a0;&#x000b1;&#x000a0;1.4</td><td char="." align="char">0.135</td><td align="left">7.0&#x000a0;&#x000b1;&#x000a0;1.6 (n&#x000a0;=&#x000a0;54)</td><td align="left">6.7&#x000a0;&#x000b1;&#x000a0;1.7 (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.248</td><td char="&#x000b1;" align="char">&#x02212;0.41&#x000a0;&#x000b1;&#x000a0;0.20 (n&#x000a0;=&#x000a0;52)</td><td char="&#x000b1;" align="char">&#x02212;0.49&#x000a0;&#x000b1;&#x000a0;0.19 (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.780</td></tr><tr><td align="left">HbA1c, %</td><td align="left">7.0&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left">6.9&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="." align="char">0.737</td><td align="left">6.5&#x000a0;&#x000b1;&#x000a0;0.6 (n&#x000a0;=&#x000a0;54)</td><td align="left">6.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td char="." align="char">0.412</td><td char="&#x000b1;" align="char">&#x02212;0.47&#x000a0;&#x000b1;&#x000a0;0.08 (n&#x000a0;=&#x000a0;52)</td><td char="&#x000b1;" align="char">&#x02212;0.34&#x000a0;&#x000b1;&#x000a0;0.07 (n&#x000a0;=&#x000a0;57)</td><td char="." align="char">0.211</td></tr><tr><td align="left">1,5AG, &#x000b5;g/mL</td><td align="left">13.9 [8.3&#x02013;20.3] (n&#x000a0;=&#x000a0;52)</td><td align="left">15.6 [10.7&#x02013;22.8] (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.086</td><td align="left">16.4 [8.7&#x02013;22.6]</td><td align="left">15.1 [9.6&#x02013;25.0] (n&#x000a0;=&#x000a0;59)</td><td char="." align="char">0.747</td><td char="&#x000b1;" align="char">2.55&#x000a0;&#x000b1;&#x000a0;0.82 (n&#x000a0;=&#x000a0;52)</td><td char="&#x000b1;" align="char">0.95&#x000a0;&#x000b1;&#x000a0;0.79 (n&#x000a0;=&#x000a0;57)</td><td char="." align="char">0.165</td></tr><tr><td align="left">NT-proBNP, pg/mL</td><td align="left">111.5 [42.1&#x02013;240.8] (n&#x000a0;=&#x000a0;52)</td><td align="left">99.6 [52.1&#x02013;234.9] (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.848</td><td align="left">114.5 [51.8&#x02013;261.9]</td><td align="left">114.1 [60.2&#x02013;323.8] (n&#x000a0;=&#x000a0;59)</td><td char="." align="char">0.673</td><td char="&#x000b1;" align="char">0.09&#x000a0;&#x000b1;&#x000a0;0.08 (n&#x000a0;=&#x000a0;52)</td><td char="&#x000b1;" align="char">0.16&#x000a0;&#x000b1;&#x000a0;0.08 (n&#x000a0;=&#x000a0;57)</td><td char="." align="char">0.535</td></tr><tr><td align="left">High-sensitive CRP, ng/mL</td><td align="left">540 [279&#x02013;1100] (n&#x000a0;=&#x000a0;52)</td><td align="left">576 [236&#x02013;1618] (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.952</td><td align="left">478 [232&#x02013;1150] (n&#x000a0;=&#x000a0;55)</td><td align="left">478 [199&#x02013;1590] (n&#x000a0;=&#x000a0;59)</td><td char="." align="char">0.984</td><td char="&#x000b1;" align="char">&#x02212;0.06&#x000a0;&#x000b1;&#x000a0;0.16 (n&#x000a0;=&#x000a0;52)</td><td char="&#x000b1;" align="char">&#x02212;0.06&#x000a0;&#x000b1;&#x000a0;0.15 (n&#x000a0;=&#x000a0;57)</td><td char="." align="char">0.983</td></tr><tr><td align="left">Current smoker, n (%)</td><td align="left">8 (17.4) (n&#x000a0;=&#x000a0;46)</td><td align="left">13 (28.3) (n&#x000a0;=&#x000a0;46)</td><td char="." align="char">0.321</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Hypertension, n (%)</td><td align="left">45 (81.8)</td><td align="left">46 (76.7)</td><td char="." align="char">0.497</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Dyslipidemia, n (%)</td><td align="left">42 (76.4)</td><td align="left">42 (70.0)</td><td char="." align="char">0.530</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Cerebrovascular disease, n (%)</td><td align="left">8 (14.6)</td><td align="left">4 (6.7)</td><td char="." align="char">0.226</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Cardiovascular disease, n (%)</td><td align="left">38 (69.1)</td><td align="left">41 (68.3)</td><td char="." align="char">0.930</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Chronic heart failure, n (%)</td><td align="left">3 (5.5)</td><td align="left">7 (11.7)</td><td char="." align="char">0.326</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="10">Medications</td></tr><tr><td align="left">&#x000a0;ACE inhibitor or ARB</td><td align="left">37 (67.3)</td><td align="left">42 (70.0)</td><td char="." align="char">0.753</td><td align="left">39 (70.9)</td><td align="left">41 (68.3)</td><td char="." align="char">0.764</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x003b2;-blocker</td><td align="left">12 (21.8)</td><td align="left">11 (18.3)</td><td char="." align="char">0.641</td><td align="left">13 (23.6)</td><td align="left">12 (20.0)</td><td char="." align="char">0.637</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Diuretic</td><td align="left">17 (30.9)</td><td align="left">12 (20.0)</td><td char="." align="char">0.178</td><td align="left">16 (29.1)</td><td align="left">15 (25.0)</td><td char="." align="char">0.621</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Statin</td><td align="left">42 (76.4)</td><td align="left">40 (66.7)</td><td char="." align="char">0.251</td><td align="left">39 (70.9)</td><td align="left">39 (65.0)</td><td char="." align="char">0.498</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x003b1;-Glucosidase inhibitor, n (%)</td><td align="left">23 (41.8)</td><td align="left">30 (50.0)</td><td char="." align="char">0.455</td><td align="left">18 (32.7)</td><td align="left">38 (63.3)</td><td char="." align="char">0.001</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Glinide, n (%)</td><td align="left">4 (7.3)</td><td align="left">4 (6.7)</td><td char="." align="char">0.899</td><td align="left">2 (3.6)</td><td align="left">5 (8.3)</td><td char="." align="char">0.293</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Biguanide, n (%)</td><td align="left">9 (16.4)</td><td align="left">10 (16.7)</td><td char="." align="char">0.965</td><td align="left">12 (21.8)</td><td align="left">16 (26.7)</td><td char="." align="char">0.545</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Sulfonylurea, n (%)</td><td align="left">9 (16.4)</td><td align="left">12 (20.0)</td><td char="." align="char">0.638</td><td align="left">4 (7.3)</td><td align="left">18 (30.0)</td><td char="." align="char">0.002</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Thiazolidinedione, n (%)</td><td align="left">11 (20.0)</td><td align="left">18 (30.0)</td><td char="." align="char">0.283</td><td align="left">9 (16.4)</td><td align="left">23 (38.3)</td><td char="." align="char">0.009</td><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Data for categorical variables are given as number (%); data for continuous variables given as mean&#x000a0;&#x000b1;&#x000a0;standard deviation or median [interquartile range]. Skewed data was calculated after logarithmic translation. In the right column, values are shown as baseline-adjusted least square mean&#x000a0;&#x000b1;&#x000a0;standard error</p><p>
<italic>BP</italic> blood pressure, <italic>HDL</italic> high-density lipoprotein, <italic>eGFR</italic> estimated glomerular filtration rate, <italic>1,5AG</italic> 1,5-anhydroglucitol,1,4-anhydro-<sc>d</sc>-glucitol, <italic>NT-proBNP</italic> N-terminal&#x000a0;pro-brain natriuretic peptide, <italic>CRP</italic> C-reactive protein. <italic>ACE</italic> angiotensin-converting enzyme, <italic>ARB</italic> angiotensin receptor blocker</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>Data were expressed as mean&#x000a0;&#x000b1;&#x000a0;standard deviation for normally distributed variables, median and interquartile range for variables with a skewed distribution, and frequencies (%) for categorical variables. All reported probability values were two-sided with a p value&#x000a0;&#x0003c;0.05 considered statistically significant. The percentage changes in the variables during the study period were calculated as (values obtained at 12 or 24&#x000a0;months after treatment randomization&#x02014;the baseline value)/baseline value. The differences between the two groups were assessed, where appropriate, by either the Student&#x02019;s <italic>t</italic> test, Mann&#x02013;Whitney test, or Fisher&#x02019;s exact test. Variables with a skewed distribution were analyzed in the analysis of covariance after logarithmic conversion. We performed baseline-adjusted and multivariable regression analysis to confirm differences between the two groups. All the analyses were conducted using the JMP software program, version 12.1.0 (SAS Institute Inc., Cary, NC, USA).</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Clinical characteristics</title><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows a comparison of the clinical characteristics at baseline and at 24&#x000a0;months and baseline-adjusted changes after 24&#x000a0;months of glycemic control between the two patient groups. There was no difference in body mass index and blood pressure between the groups throughout the study, while heart rate was increased in the sitagliptin group at 24&#x000a0;months. Although more than 70% of the subjects had hypertension, blood pressure was well controlled in both groups. Other parameters, such as lipid and renal profiles, were similar in the two groups throughout the study. The incidence of a previous history of CV diseases, including heart failure was not different in the two groups. Although the use of background medications for hypertension, dyslipidemia, or diabetes at baseline was also comparable in the groups, the incidence of some types of antidiabetic agent increased during the treatment period. This was especially apparent in the conventional group, possibly due to many patients achieving the glycemic control goal (HbA1c&#x000a0;&#x0003c;6.2%) set in the PROLOGUE study protocol.</p></sec><sec id="Sec10"><title>Glycemic control and neurohumoral effects</title><p>The levels of fasting plasma glucose, HbA1c, and 1, 5 AG were similar at baseline in the two groups and there were no significant changes in these parameters during the 24&#x000a0;months of treatment between the groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). These results indicate similar degrees of improved glycemic control had been achieved. The serum levels of NT-proBNP and high-sensitive CRP were also similar at baseline and after 24&#x000a0;months of treatment.</p></sec><sec id="Sec11"><title>Echocardiographic parameters</title><p>A comparison of echocardiographic parameters at baseline and after 24&#x000a0;months of treatment and baseline-adjusted changes after 24&#x000a0;months of treatment in both groups is shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Although baseline E/e&#x02032; was significantly higher in the sitagliptin group than in the conventional group, the baseline-adjusted change in E/e&#x02032; during 24&#x000a0;months of treatment was significantly lower in the sitagliptin group than in the conventional group (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Analysis of covariance showed this difference remained significant (sitagliptin group, &#x02212;30.9&#x000a0;&#x000b1;&#x000a0;9.8%/24&#x000a0;months; conventional group, &#x02212;11.0&#x000a0;&#x000b1;&#x000a0;9.0%/24&#x000a0;months; p&#x000a0;=&#x000a0;0.001, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), even after adjustment for various confounding factors, such as age, sex, baseline systolic blood pressure, baseline HbA1c, history of CV diseases, history of heart failure, baseline medications for diabetes, baseline E/A, baseline LVEF, and baseline LV mass index. Other parameters relevant to diastolic function such as e&#x02032;, E/A, and DT were similar in the two groups during the 24&#x000a0;months of treatment (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). There were also no significant differences in parameters of cardiac structure and systolic function at baseline and 24&#x000a0;months, or baseline-adjusted changes after 24&#x000a0;months of treatment between the two groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c, d).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Comparisons of echocardiographic parameters at baseline, 24&#x000a0;months and baseline-adjusted changes after 24&#x000a0;months of glycemic control</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="3">Baseline</th><th align="left" colspan="3">24&#x000a0;months</th><th align="left" colspan="3">Least square means of baseline-adjusted changes</th></tr><tr><th align="left">Sitagliptin (n&#x000a0;=&#x000a0;55)</th><th align="left">Conventional (n&#x000a0;=&#x000a0;60)</th><th align="left">p value</th><th align="left">Sitagliptin (n&#x000a0;=&#x000a0;55)</th><th align="left">Conventional (n&#x000a0;=&#x000a0;60)</th><th align="left">p value</th><th align="left">Sitagliptin (n&#x000a0;=&#x000a0;55)</th><th align="left">Conventional (n&#x000a0;=&#x000a0;60)</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">TMF-E, cm/s</td><td char="&#x000b1;" align="char">74.2&#x000a0;&#x000b1;&#x000a0;32.6</td><td char="&#x000b1;" align="char">69.3&#x000a0;&#x000b1;&#x000a0;31.0</td><td char="." align="char">0.417</td><td char="&#x000b1;" align="char">73.1&#x000a0;&#x000b1;&#x000a0;33.4</td><td char="&#x000b1;" align="char">73.6&#x000a0;&#x000b1;&#x000a0;34.3</td><td char="." align="char">0.939</td><td char="&#x000b1;" align="char">&#x02212;0.85&#x000a0;&#x000b1;&#x000a0;2.37</td><td char="&#x000b1;" align="char">4.04&#x000a0;&#x000b1;&#x000a0;2.27</td><td char="." align="char">0.139</td></tr><tr><td align="left">e&#x02032;, cm/s</td><td char="&#x000b1;" align="char">6.35&#x000a0;&#x000b1;&#x000a0;1.72</td><td char="&#x000b1;" align="char">7.03&#x000a0;&#x000b1;&#x000a0;2.13</td><td char="." align="char">0.065</td><td char="&#x000b1;" align="char">6.60&#x000a0;&#x000b1;&#x000a0;2.19</td><td char="&#x000b1;" align="char">6.76&#x000a0;&#x000b1;&#x000a0;2.11</td><td char="." align="char">0.684</td><td char="&#x000b1;" align="char">0.13&#x000a0;&#x000b1;&#x000a0;0.23</td><td char="&#x000b1;" align="char">&#x02212;0.16&#x000a0;&#x000b1;&#x000a0;0.22</td><td char="." align="char">0.370</td></tr><tr><td align="left">E/e&#x02032;</td><td char="&#x000b1;" align="char">12.17&#x000a0;&#x000b1;&#x000a0;5.20</td><td char="&#x000b1;" align="char">10.34&#x000a0;&#x000b1;&#x000a0;4.18</td><td char="." align="char">0.040</td><td char="&#x000b1;" align="char">12.19&#x000a0;&#x000b1;&#x000a0;6.93</td><td char="&#x000b1;" align="char">12.06&#x000a0;&#x000b1;&#x000a0;7.06</td><td char="." align="char">0.922</td><td char="&#x000b1;" align="char">&#x02212;0.18&#x000a0;&#x000b1;&#x000a0;0.55</td><td char="&#x000b1;" align="char">1.91&#x000a0;&#x000b1;&#x000a0;0.53</td><td char="." align="char">0.008</td></tr><tr><td align="left">TMF-A, cm/s</td><td char="&#x000b1;" align="char">80.1&#x000a0;&#x000b1;&#x000a0;20.3 (n&#x000a0;=&#x000a0;48)</td><td char="&#x000b1;" align="char">83.4&#x000a0;&#x000b1;&#x000a0;21.3 (n&#x000a0;=&#x000a0;54)</td><td char="." align="char">0.424</td><td char="&#x000b1;" align="char">82.4&#x000a0;&#x000b1;&#x000a0;19.3 (n&#x000a0;=&#x000a0;48)</td><td char="&#x000b1;" align="char">88.2&#x000a0;&#x000b1;&#x000a0;22.9 (n&#x000a0;=&#x000a0;55)</td><td char="." align="char">0.168</td><td char="&#x000b1;" align="char">3.06&#x000a0;&#x000b1;&#x000a0;2.10 (n&#x000a0;=&#x000a0;47)</td><td char="&#x000b1;" align="char">5.73&#x000a0;&#x000b1;&#x000a0;1.96 (n&#x000a0;=&#x000a0;54)</td><td char="." align="char">0.354</td></tr><tr><td align="left">E/A</td><td char="&#x000b1;" align="char">0.91&#x000a0;&#x000b1;&#x000a0;0.52(n&#x000a0;=&#x000a0;48)</td><td char="&#x000b1;" align="char">0.79&#x000a0;&#x000b1;&#x000a0;0.24 (n&#x000a0;=&#x000a0;54)</td><td char="." align="char">0.125</td><td char="&#x000b1;" align="char">0.86&#x000a0;&#x000b1;&#x000a0;0.35 (n&#x000a0;=&#x000a0;48)</td><td char="&#x000b1;" align="char">0.81&#x000a0;&#x000b1;&#x000a0;0.31 (n&#x000a0;=&#x000a0;54)</td><td char="." align="char">0.418</td><td char="&#x000b1;" align="char">&#x02212;0.03&#x000a0;&#x000b1;&#x000a0;0.04 (n&#x000a0;=&#x000a0;48)</td><td char="&#x000b1;" align="char">&#x02212;0.04&#x000a0;&#x000b1;&#x000a0;0.04 (n&#x000a0;=&#x000a0;54)</td><td char="." align="char">0.825</td></tr><tr><td align="left">Deceleration time, msec</td><td char="&#x000b1;" align="char">233.5&#x000a0;&#x000b1;&#x000a0;65.8 (n&#x000a0;=&#x000a0;50)</td><td char="&#x000b1;" align="char">237.6&#x000a0;&#x000b1;&#x000a0;67.7 (n&#x000a0;=&#x000a0;55)</td><td char="." align="char">0.751</td><td char="&#x000b1;" align="char">238.1&#x000a0;&#x000b1;&#x000a0;78.1 (n&#x000a0;=&#x000a0;52)</td><td char="&#x000b1;" align="char">240.6&#x000a0;&#x000b1;&#x000a0;64.6 (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.859</td><td char="&#x000b1;" align="char">9.53&#x000a0;&#x000b1;&#x000a0;9.06 (n&#x000a0;=&#x000a0;49)</td><td char="&#x000b1;" align="char">5.38&#x000a0;&#x000b1;&#x000a0;8.63 (n&#x000a0;=&#x000a0;54)</td><td char="." align="char">0.741</td></tr><tr><td align="left">LV end-diastolic dimension, mm</td><td char="&#x000b1;" align="char">48.5&#x000a0;&#x000b1;&#x000a0;5.6</td><td char="&#x000b1;" align="char">48.6&#x000a0;&#x000b1;&#x000a0;5.9</td><td char="." align="char">0.912</td><td char="&#x000b1;" align="char">47.5&#x000a0;&#x000b1;&#x000a0;5.7</td><td char="&#x000b1;" align="char">47.7&#x000a0;&#x000b1;&#x000a0;5.3</td><td char="." align="char">0.836</td><td char="&#x000b1;" align="char">&#x02212;1.04&#x000a0;&#x000b1;&#x000a0;0.51</td><td char="&#x000b1;" align="char">&#x02212;0.91&#x000a0;&#x000b1;&#x000a0;0.48</td><td char="." align="char">0.855</td></tr><tr><td align="left">LV end-systolic dimension, mm</td><td char="&#x000b1;" align="char">31.7&#x000a0;&#x000b1;&#x000a0;6.1</td><td char="&#x000b1;" align="char">32.6&#x000a0;&#x000b1;&#x000a0;7.2</td><td char="." align="char">0.462</td><td char="&#x000b1;" align="char">31.5&#x000a0;&#x000b1;&#x000a0;7.1</td><td char="&#x000b1;" align="char">31.6&#x000a0;&#x000b1;&#x000a0;6.9</td><td char="." align="char">0.935</td><td char="&#x000b1;" align="char">&#x02212;0.30&#x000a0;&#x000b1;&#x000a0;0.60</td><td char="&#x000b1;" align="char">&#x02212;0.94&#x000a0;&#x000b1;&#x000a0;0.58</td><td char="." align="char">0.447</td></tr><tr><td align="left">Fractional shortening, &#x000a0;%</td><td char="&#x000b1;" align="char">35.1&#x000a0;&#x000b1;&#x000a0;6.7</td><td char="&#x000b1;" align="char">33.6&#x000a0;&#x000b1;&#x000a0;7.9</td><td char="." align="char">0.279</td><td char="&#x000b1;" align="char">33.9&#x000a0;&#x000b1;&#x000a0;13.3</td><td char="&#x000b1;" align="char">34.4&#x000a0;&#x000b1;&#x000a0;8.5</td><td char="." align="char">0.787</td><td char="&#x000b1;" align="char">&#x02212;1.05&#x000a0;&#x000b1;&#x000a0;1.31</td><td char="&#x000b1;" align="char">0.64&#x000a0;&#x000b1;&#x000a0;1.25</td><td char="." align="char">0.355</td></tr><tr><td align="left">LV ejection fraction, &#x000a0;%</td><td char="&#x000b1;" align="char">63.6&#x000a0;&#x000b1;&#x000a0;9.6</td><td char="&#x000b1;" align="char">60.8&#x000a0;&#x000b1;&#x000a0;10.8</td><td char="." align="char">0.153</td><td char="&#x000b1;" align="char">62.5&#x000a0;&#x000b1;&#x000a0;9.3</td><td char="&#x000b1;" align="char">61.9&#x000a0;&#x000b1;&#x000a0;9.8</td><td char="." align="char">0.721</td><td char="&#x000b1;" align="char">&#x02212;0.63&#x000a0;&#x000b1;&#x000a0;0.85 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">0.67&#x000a0;&#x000b1;&#x000a0;0.81</td><td char="." align="char">0.273</td></tr><tr><td align="left">LV mass, g</td><td char="&#x000b1;" align="char">173.0&#x000a0;&#x000b1;&#x000a0;66.6</td><td char="&#x000b1;" align="char">160.2&#x000a0;&#x000b1;&#x000a0;56.3</td><td char="." align="char">0.266</td><td char="&#x000b1;" align="char">159.9&#x000a0;&#x000b1;&#x000a0;49.1</td><td char="&#x000b1;" align="char">159.2&#x000a0;&#x000b1;&#x000a0;52.9</td><td char="." align="char">0.940</td><td char="&#x000b1;" align="char">&#x02212;10.29&#x000a0;&#x000b1;&#x000a0;4.94</td><td char="&#x000b1;" align="char">&#x02212;3.50&#x000a0;&#x000b1;&#x000a0;4.73</td><td char="." align="char">0.324</td></tr><tr><td align="left">LV mass index, g/m<sup>2</sup>
</td><td char="&#x000b1;" align="char">101.6&#x000a0;&#x000b1;&#x000a0;35.0</td><td char="&#x000b1;" align="char">96.2&#x000a0;&#x000b1;&#x000a0;30.6</td><td char="." align="char">0.383</td><td char="&#x000b1;" align="char">94.8&#x000a0;&#x000b1;&#x000a0;26.3</td><td char="&#x000b1;" align="char">95.6&#x000a0;&#x000b1;&#x000a0;28.3</td><td char="." align="char">0.881</td><td char="&#x000b1;" align="char">&#x02212;5.50&#x000a0;&#x000b1;&#x000a0;2.81</td><td char="&#x000b1;" align="char">&#x02212;1.80&#x000a0;&#x000b1;&#x000a0;2.68</td><td char="." align="char">0.343</td></tr><tr><td align="left">Relative wall thickness</td><td char="&#x000b1;" align="char">0.40&#x000a0;&#x000b1;&#x000a0;0.09</td><td char="&#x000b1;" align="char">0.38&#x000a0;&#x000b1;&#x000a0;0.08</td><td char="." align="char">0.230</td><td char="&#x000b1;" align="char">0.41&#x000a0;&#x000b1;&#x000a0;0.08</td><td char="&#x000b1;" align="char">0.39&#x000a0;&#x000b1;&#x000a0;0.08</td><td char="." align="char">0.400</td><td char="&#x000b1;" align="char">0.01&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="left">0.00&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="." align="char">0.886</td></tr><tr><td align="left">LA dimension, mm</td><td char="&#x000b1;" align="char">40.8&#x000a0;&#x000b1;&#x000a0;6.9 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">40.0&#x000a0;&#x000b1;&#x000a0;7.6 (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.572</td><td char="&#x000b1;" align="char">39.7&#x000a0;&#x000b1;&#x000a0;6.9</td><td char="&#x000b1;" align="char">40.3&#x000a0;&#x000b1;&#x000a0;6.9 (n&#x000a0;=&#x000a0;59)</td><td char="." align="char">0.652</td><td char="&#x000b1;" align="char">&#x02212;0.87&#x000a0;&#x000b1;&#x000a0;0.55 (n&#x000a0;=&#x000a0;54)</td><td char="&#x000b1;" align="char">0.25&#x000a0;&#x000b1;&#x000a0;0.54 (n&#x000a0;=&#x000a0;58)</td><td char="." align="char">0.151</td></tr></tbody></table><table-wrap-foot><p>Data for categorical variables are given as number (%); data for continuous variables given as mean&#x000a0;&#x000b1;&#x000a0;standard deviation. In the right column, values are shown as baseline-adjusted least square mean&#x000a0;&#x000b1;&#x000a0;standard error</p><p>
<italic>TMF</italic> transmitral flow velocity, <italic>E</italic> early diastolic velocity, <italic>e&#x02032;</italic> early diastolic mitral annular velocity, <italic>LV</italic> left ventricular, <italic>LA</italic> left atrial</p></table-wrap-foot></table-wrap>
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Percentage changes in E/e&#x02032;, e&#x02032;, LVEF, and LVMI at 12 and 24&#x000a0;months in the two treatment groups. Each graph shows sex-, age- and baseline-adjusted least square means (&#x000b1;standard error) at 12 and 24&#x000a0;months. The %change values were calculated as (24 or 12&#x000a0;month data-baseline)/baseline. E/e&#x02032; at 24&#x000a0;months shows significant difference between the two groups. <italic>E</italic> peak early diastolic transmitral flow velocity, <italic>e&#x02032;</italic> peak early diastolic mitral annular velocity, <italic>LVEF</italic> left ventricular ejection fraction, <italic>LVMI</italic> left ventricular mass index. *p&#x000a0;=&#x000a0;0.002 vs. sitagliptin group</p></caption><graphic xlink:href="12933_2017_546_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Factors associated with change in E/e&#x02032; from baseline to 24&#x000a0;months</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="2">Model 1</th><th align="left" colspan="2">Model 2</th><th align="left" colspan="2">Model 3</th></tr><tr><th align="left" colspan="2">N&#x000a0;=&#x000a0;115, R&#x000a0;=&#x000a0;0.26</th><th align="left" colspan="2">N&#x000a0;=&#x000a0;115, R&#x000a0;=&#x000a0;0.27</th><th align="left" colspan="2">N&#x000a0;=&#x000a0;115, R&#x000a0;=&#x000a0;0.55</th></tr><tr><th align="left">&#x003b2;</th><th align="left">p value</th><th align="left">&#x003b2;</th><th align="left">p value</th><th align="left">&#x003b2;</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">Sitagliptin</td><td char="." align="char">&#x02212;8.910</td><td char="." align="char">0.006</td><td char="." align="char">&#x02212;8.887</td><td char="." align="char">0.007</td><td char="." align="char">&#x02212;9.959</td><td char="." align="char">0.001</td></tr><tr><td align="left">E/e&#x02032;</td><td char="." align="char">&#x02212;0.094</td><td char="." align="char">0.889</td><td char="." align="char">&#x02212;0.159</td><td char="." align="char">0.820</td><td char="." align="char">&#x02212;0.240</td><td char="." align="char">0.716</td></tr><tr><td align="left">Male gender</td><td align="left"/><td align="left"/><td char="." align="char">0.674</td><td char="." align="char">0.845</td><td char="." align="char">0.149</td><td char="." align="char">0.966</td></tr><tr><td align="left">Age</td><td align="left"/><td align="left"/><td char="." align="char">0.330</td><td char="." align="char">0.392</td><td char="." align="char">&#x02212;0.005</td><td char="." align="char">0.990</td></tr><tr><td align="left">Systolic blood pressure</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02212;0.293</td><td char="." align="char">0.095</td></tr><tr><td align="left">HbA1c</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">6.614</td><td char="." align="char">0.272</td></tr><tr><td align="left">Cardiovascular disease</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02212;5.631</td><td char="." align="char">0.142</td></tr><tr><td align="left">Chronic heart failure</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">10.819</td><td char="." align="char">0.070</td></tr><tr><td align="left">&#x003b1;-glucosidase inhibitor</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">1.053</td><td char="." align="char">0.734</td></tr><tr><td align="left">Biguanide</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02212;14.839</td><td char="." align="char">0.001</td></tr><tr><td align="left">Glinide</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02212;10.778</td><td char="." align="char">0.072</td></tr><tr><td align="left">Sulfonylurea</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02212;0.567</td><td char="." align="char">0.891</td></tr><tr><td align="left">Thiazolidinedione</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">2.159</td><td char="." align="char">0.572</td></tr><tr><td align="left">LV ejection fraction</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.178</td><td char="." align="char">0.602</td></tr><tr><td align="left">LV mass index</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.348</td><td char="." align="char">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Model 1 means ANCOVA adjusted for baseline E/e&#x02032;. Model 2 were adjusted for Model 1 and sex, age. Model 3 were adjusted for Model 2 and systolic blood pressure, HbA1c, cardiovascular disease, chronic heart failure, &#x003b1;-glucosidase inhibitor, bigunaide, glinide, sulfonylurea, thiazolidinedione, LV ejection fraction, LV mass index, whose data were obtained at baseline examination</p><p>Abbreviations, see Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>
</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p>The present study was a subgroup analysis of the PROLOGUE trial that focused on the effect of sitagliptin on echocardiographic parameters of diastolic function. The key finding of the study was that addition of sitagliptin to conventional diabetic care significantly attenuated the increase in echocardiographic parameters of diastolic function (E/e&#x02032;), relative to conventional treatment alone. On the other hand, changes in other parameters such as LV size and LVEF did not differ between the two groups. We also found no significant differences in the biomarkers measured during the study. It is known that metabolic disturbances and diabetes are associated closely with cardiac diastolic dysfunction such as diabetic cardiomyopathy, and there is also evidence that patients with diabetes and an increased E/e&#x02032; have higher mortality [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Given these results, it appears that sitagliptin treatment may have a protective effect on cardiac diastolic function, leading to improved prognosis independent of glycemic control and blood pressure.</p><p>Recently we demonstrated a possible effect of sitagliptin on carotid atherosclerosis [<xref ref-type="bibr" rid="CR18">18</xref>], endothelial function [<xref ref-type="bibr" rid="CR24">24</xref>], and arterial stiffness [<xref ref-type="bibr" rid="CR25">25</xref>] using data of the PROLOGUE study. This series of studies did not show beneficial effects of sitagliptin treatment on these variables, relative to conventional glucose-lowering treatment with the exception of incretin-related agents, with better glycemic control being observed in the sitagliptin treatment group. In contrast, there is another report that additional administration of DPP-4 inhibitors, including sitagliptin, to conventional antidiabetic regimes significantly attenuated the progression of carotid IMT [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Although the participants&#x02019; backgrounds including age, concomitant agents, and severity of diabetes differed between these studies [<xref ref-type="bibr" rid="CR18">18</xref>], these findings suggest that DPP-4 inhibitors at least cause no harm to the vasculature and are useful for glycemic control in the usual clinical settings. The findings are also consistent with the results of a large CV outcome trial [<xref ref-type="bibr" rid="CR13">13</xref>]. This led us to investigate the effect of sitagliptin on cardiac function and biomarkers in the current sub-group analysis of the PROLOGUE study data.</p><p>DPP-4 inhibitors promote glucose-dependent insulin secretion and suppress glucagon secretion by inhibiting the activity of an enzyme which inactivates endogenous incretin like glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide. This leads to improved postprandial hyperglycemia similar to that seen with the normal physiological response. DPP-4 inhibitors do not cause weight gain and a single administration is unlikely to induce hypoglycemia. It is therefore relatively easy to use DPP-4 inhibitors safely in the elderly and patients with renal dysfunction. To date, the three randomized clinical trials mentioned above have reported non-inferiority, relative to placebo, for CV outcomes in patients with T2DM with high cardiovascular risk or established CV disease [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. In particular, the rate of hospitalization for heart failure was similar between sitagliptin and placebo treatments in the TECOS trial [<xref ref-type="bibr" rid="CR13">13</xref>], despite the SAVOR-TIMI 53 trial showing that saxagliptin, another DPP-4 inhibitor, significantly increased the hospitalization rate [<xref ref-type="bibr" rid="CR12">12</xref>]. However, because these trials did not fully investigate CV physiological functions and relevant biomarkers, it proved difficult to determine how DPP-4 inhibitors affected cardiac function. Mechanistic studies using these surrogate markers are therefore required to determine the possible actions of DPP-4 inhibitors on the CV system.</p><p>Accumulated evidence suggests that patients with TD2M often exhibit LV diastolic dysfunction and heart failure due to underlying metabolic derangement, such as insulin resistance, independent of hypertension and coronary artery disease (CAD) [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Recent studies have also demonstrated that DPP-4 activity correlates with cardiac systolic and diastolic dysfunction and remodeling via several molecular pathways, such as increased inflammation and altered angiogenesis [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. Experimental studies have shown that sitagliptin improved survival rate and cardiac function in an ischemia&#x02013;reperfusion mice model [<xref ref-type="bibr" rid="CR35">35</xref>] and reduced infarction size in a myocardial infarction mice model [<xref ref-type="bibr" rid="CR36">36</xref>]. Long-term administration of sitagliptin was also shown to suppress the onset of heart failure in a rat model of heart failure [<xref ref-type="bibr" rid="CR31">31</xref>]. A meta-analysis of clinical trials also described the advantages of DPP-4 inhibitors on risk reduction in CV events and death compared with other antidiabetic agents [<xref ref-type="bibr" rid="CR37">37</xref>]. Sitagliptin treatment in T2DM patients with CAD also improved parameters of diastolic function and cardiac dysfunction due to post-ischemic stunning during dobutamine stress echocardiography [<xref ref-type="bibr" rid="CR38">38</xref>]. In contrast, sitagliptin treatment did not improve systolic function in T2DM patients with ischemic heart failure [<xref ref-type="bibr" rid="CR39">39</xref>]. Furthermore, Oe et al. [<xref ref-type="bibr" rid="CR40">40</xref>] reported that sitagliptin treatment in T2DM patients with LV diastolic dysfunction was not associated with improvement in the relevant echocardiographic parameters. As a consequence of these different findings the therapeutic effect of DPP-4 inhibitors on cardiac function remains controversial.</p><p>In the present study, adding sitagliptin to usual diabetes treatment significantly attenuated the annual increase in E/e&#x02032;, suggesting a preventive effect on LV compliance and diastolic dysfunction. However, sitagliptin treatment did not affect other echocardiographic parameters of systolic function and cardiac structures or other clinical variables, such as NT-proBNP, blood pressure, and glycemic control. Comparison with a previous study in which sitagliptin did not improve diastolic dysfunction [<xref ref-type="bibr" rid="CR40">40</xref>] showed the following differences: (1) all participants in the previous study were diagnosed with diastolic dysfunction at baseline; (2) the treatment period was 6&#x000a0;months vs. 24&#x000a0;months in the PROLOGUE study; (3) the comparator was voglibose vs. any antidiabetic agents except for incretin-related in the PROLOGUE study. While these differences may have affected the results of the studies, the precise mechanisms by which sitagliptin suppressed the increase in diastolic parameter values were not confirmed in our study. As reported previously [<xref ref-type="bibr" rid="CR40">40</xref>], the increased incidence of concomitant use of thiazolidinediones in the conventional group may have enhanced the acceleration of E/e&#x02032; values. Nogueira et al. also reported that beneficial effects in LV diastolic function were observed in T2DM patients on insulin treated with sitagliptin, while the effects were not as apparent in T2DM patients treated with insulin only [<xref ref-type="bibr" rid="CR41">41</xref>]. That study also reported a possible association between the sitagliptin-mediated improvement in diastolic dysfunction and increase in plasma GLP-1 levels. However, we did not measure this incretin in the current study. It is thought that GLP-1 has a wide spectrum of CV protective effects [<xref ref-type="bibr" rid="CR42">42</xref>]. In fact, treatment with a GLP-1 agonist, one of the incretin-related agents, was shown to improve diastolic function beyond and independent of glycemic control [<xref ref-type="bibr" rid="CR43">43</xref>]. Because there remains clinical caution regarding DPP-4 inhibitor-induced heart failure [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], further experimental and clinical research is required to elucidate the precise mechanisms by which DPP-4 inhibitors affect diastolic function and heart failure in patients with T2DM.</p><sec id="Sec13"><title>Limitations</title><p>The present study was a sub-analysis of the PROLOGUE study. Because echocardiography was a voluntary measurement in the PROLOGUE study and not performed in all participants, the number of patients in this study was small and included only Japanese subjects. Whether or not echocardiography was performed was left to the judgment of each researcher and therefore selection bias could not be fully excluded. The sample size may therefore be underpowered and accordingly the clinical implications may be limited. In addition, the PROLOGUE study recruited patients with and without history of heart failure at baseline, with patients with a NYHA functional classification of III and IV being excluded. Because most patients had no history of heart failure evident at baseline, we did not determine whether there were differences in the effects of sitagliptin on diastolic function between patients with or without heart failure. Further studies on a larger number of subjects are needed to assess whether longer-term DPP-4 inhibitor treatment is safe and has beneficial effect on cardiac function in T2DM patients with or without overt heart failure.</p></sec></sec><sec id="Sec14" sec-type="conclusion"><title>Conclusions</title><p>Our present sub-group analysis from the PROLOGUE study demonstrated that adding sitagliptin to conventional antidiabetic regimens for 24&#x000a0;months in patients with T2DM attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction, E/e&#x02032;, independent of other clinical variables such as blood pressure and glycemic control. These results suggest that sitagliptin is potentially a beneficial agent for diastolic function in patients with T2DM.</p></sec></body><back><app-group><app id="App1"><sec id="Sec15"><title>Additional file</title><p>
<media position="anchor" xlink:href="12933_2017_546_MOESM1_ESM.docx" id="MOESM1"><caption><p>
<bold>Additional file 1.</bold> The PROLOGUE Study Investigators.</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>A</term><def><p>peak atrial systolic transmitral flow velocity</p></def></def-item><def-item><term>CAD</term><def><p>coronary artery disease</p></def></def-item><def-item><term>CV</term><def><p>cardiovascular</p></def></def-item><def-item><term>DPP-4</term><def><p>dipeptidyl peptidase 4</p></def></def-item><def-item><term>DT</term><def><p>deceleration time</p></def></def-item><def-item><term>E</term><def><p>peak early diastolic transmitral flow velocity</p></def></def-item><def-item><term>e&#x02032;</term><def><p>peak early diastolic mitral annular velocity</p></def></def-item><def-item><term>EF</term><def><p>ejection fraction</p></def></def-item><def-item><term>GLP-1</term><def><p>glucagon-like peptide-1</p></def></def-item><def-item><term>IMT</term><def><p>intima-media thickness</p></def></def-item><def-item><term>LV</term><def><p>left ventricular</p></def></def-item><def-item><term>LVDd</term><def><p>left ventricular end-diastolic dimensions</p></def></def-item><def-item><term>LVDs</term><def><p>left ventricular end-systolic dimensions</p></def></def-item><def-item><term>NT-proBNP</term><def><p>N-terminal pro-brain natriuretic peptide</p></def></def-item><def-item><term>NYHA</term><def><p>New York Heart Association</p></def></def-item><def-item><term>TMF</term><def><p>transmitral flow</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s12933-017-0546-2) contains supplementary material, which is available to authorized users.</p></fn><fn><p>Hirotsugu Yamada and Atsushi Tanaka contributed equally to this work</p></fn></fn-group><ack><title>Authors&#x02019; contributions</title><p>HY and AT wrote the draft of the article, which was critically supervised by MS and KN. HY performed statistical analysis throughout this study. KK, RA and MM confirmed data collection and study selection criteria. HD, MI, HT, MN, HK, YKB, MO, and TM enrolled patients and performed study quality assessment. All authors approved the final version of manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p>The authors thank the participants and staff for their essential contributions to the PROLOGUE study. The PROLOGUE study is a multicenter collaboration. In addition to the listed authors, the PROLOGUE Study Investigators listed in Additional file 1 were involved in this study.</p></sec><sec id="FPar2"><title>Competing interests</title><p>HYa received honoraria from MSD, research grant from MSD and Ono. AT, KK, and RA declares no competing interests. MM received honoraria from Astellas, Eli Lilly, Mitsubishi Tanabe, Novo Nordisk, Sanofi, and Takeda, research grant from Astellas, Nihon Unisys, Nikkiso, and Terumo. HD received honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Kowa, Medtronic Japan, Mitsubishi Tanabe, Mochida, MSD, Ono, Pfizer, Sanofi, Shionogi, Takeda and Terumo, research funding from Abbott Vascular Japan, Astellas, Bayer, Boehringer Ingelheim, Boston Scientific Japan, Bristol-Myers, Daiichi Sankyo, Kaken, Kowa, MSD, Novartis, Otsuka, Pfizer, Philips Respironics GK, Sanofi, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon and Takeda. MI received honoraria from Daiichi Sankyo and Pfizer, research funding from Astellas, Biotronik, Bristol-Myers, Daiichi Sankyo, GlaxoSmithKline, Mitsubishi Tanabe, MSD, Novartis, Otsuka, Pfizer, Shionogi, Sumitomo Dainippon and Takeda. HT received honoraria from Bristol-Myers, Daiichi Sankyo, Mitsubishi Tanabe and Ono, research funding from Astellas, Boehringer Ingelheim, Boston Scientific Japan, Daiichi Sankyo, Mitsubishi Tanabe, Otsuka, Takeda and Teijin Pharma. MN declares no competing interests. HK declares no competing interests. YKB received honoraria from AstraZeneca, Mitsubishi Tanabe, MSD, and Takeda, research grant from AstraZeneca, Daiichi Sankyo, Mitsubishi Tanabe, MSD, and Takeda. MO received honoraria from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Kowa, Merck, Mitsubishi Tanabe, Novartis, Ono and Sanofi. HYo declares no competing interests. TM received honoraria from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Mitsubishi Tanabe, MSD, Pfizer, Sumitomo Dainippon, and Takeda, research grant from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Mitsubishi Tanabe, MSD, Novartis, Otsuka, Pfizer, Sanofi, Sumitomo Dainippon, Takeda, and Teijin Pharma. KN received honoraria from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Merck, Mitsubishi Tanabe, Sanofi, and Takeda. MS received honoraria from MSD, research grant from MSD and Ono. KN received research funding from Astellas, Boehringer Ingelheim, Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan, Mitsubishi Tanabe, Sanwa Kagaku Kenkyusho, Takeda, and Teijin Pharma.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p>The datasets analyzed during the current study are available from the corresponding authors on reasonable request (yamadah@tokushima-u.ac.jp, node@cc.saga-u.ac.jp).</p></sec><sec id="FPar4"><title>Consent for publication</title><p>All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language. If the manuscript is accepted, we approve it for publication in Cardiovascular Diabetology.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p>The ethical committees of the participating institutions approved the study protocol. Written informed consent for participation in the study was obtained from all subjects.</p></sec><sec id="FPar6"><title>Funding</title><p>This study is supported by a research grant from the Clinical Research Promotion Foundation (No. 1026). The funding body had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannel</surname><given-names>WB</given-names></name><name><surname>Hjortland</surname><given-names>M</given-names></name><name><surname>Castelli</surname><given-names>WP</given-names></name></person-group><article-title>Role of diabetes in congestive heart failure: the Framingham study</article-title><source>Am J Cardiol</source><year>1974</year><volume>34</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(74)90089-7</pub-id><pub-id pub-id-type="pmid">4835750</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Emerging Risk Factors C</collab></person-group><article-title>Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E et al.: diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies</article-title><source>Lancet</source><year>2010</year><volume>375</volume><issue>9733</issue><fpage>2215</fpage><lpage>2222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60484-9</pub-id><pub-id pub-id-type="pmid">20609967</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>RE</given-names></name><name><surname>Krum</surname><given-names>H</given-names></name></person-group><article-title>Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9982</issue><fpage>2107</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61402-1</pub-id><pub-id pub-id-type="pmid">26009231</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoni</surname><given-names>AG</given-names></name><name><surname>Hundley</surname><given-names>WG</given-names></name><name><surname>Massing</surname><given-names>MW</given-names></name><name><surname>Bonds</surname><given-names>DE</given-names></name><name><surname>Burke</surname><given-names>GL</given-names></name><name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name></person-group><article-title>Heart failure prevalence, incidence, and mortality in the elderly with diabetes</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><issue>3</issue><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.3.699</pub-id><pub-id pub-id-type="pmid">14988288</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>MR</given-names></name><name><surname>Petrie</surname><given-names>MC</given-names></name><name><surname>Varyani</surname><given-names>F</given-names></name><name><surname>Ostergren</surname><given-names>J</given-names></name><name><surname>Michelson</surname><given-names>EL</given-names></name><name><surname>Young</surname><given-names>JB</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><issue>11</issue><fpage>1377</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn153</pub-id><pub-id pub-id-type="pmid">18413309</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbull</surname><given-names>FM</given-names></name><name><surname>Abraira</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>RJ</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><name><surname>Chalmers</surname><given-names>JP</given-names></name><name><surname>Duckworth</surname><given-names>WC</given-names></name><name><surname>Evans</surname><given-names>GW</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Moritz</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Intensive glucose control and macrovascular outcomes in type 2 diabetes</article-title><source>Diabetologia</source><year>2009</year><volume>52</volume><issue>11</issue><fpage>2288</fpage><lpage>2298</lpage><pub-id pub-id-type="doi">10.1007/s00125-009-1470-0</pub-id><pub-id pub-id-type="pmid">19655124</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varas-Lorenzo</surname><given-names>C</given-names></name><name><surname>Margulis</surname><given-names>AV</given-names></name><name><surname>Pladevall</surname><given-names>M</given-names></name><name><surname>Riera-Guardia</surname><given-names>N</given-names></name><name><surname>Calingaert</surname><given-names>B</given-names></name><name><surname>Hazell</surname><given-names>L</given-names></name><name><surname>Romio</surname><given-names>S</given-names></name><name><surname>Perez-Gutthann</surname><given-names>S</given-names></name></person-group><article-title>The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies</article-title><source>BMC Cardiovasc Disord</source><year>2014</year><volume>14</volume><fpage>129</fpage><pub-id pub-id-type="doi">10.1186/1471-2261-14-129</pub-id><pub-id pub-id-type="pmid">25260374</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komajda</surname><given-names>M</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Beck-Nielsen</surname><given-names>H</given-names></name><name><surname>Gomis</surname><given-names>R</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name><name><surname>Curtis</surname><given-names>PS</given-names></name><name><surname>Jones</surname><given-names>NP</given-names></name><name><surname>Home</surname><given-names>PD</given-names></name></person-group><article-title>Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>7</issue><fpage>824</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp604</pub-id><pub-id pub-id-type="pmid">20118174</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name></person-group><article-title>Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored</article-title><source>Lancet Diabetes Endocrinol</source><year>2014</year><volume>2</volume><issue>10</issue><fpage>843</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(14)70031-2</pub-id><pub-id pub-id-type="pmid">24731668</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitchett</surname><given-names>DH</given-names></name><name><surname>Udell</surname><given-names>JA</given-names></name><name><surname>Inzucchi</surname><given-names>SE</given-names></name></person-group><article-title>Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes</article-title><source>Eur J Heart Fail</source><year>2017</year><volume>19</volume><issue>1</issue><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/ejhf.633</pub-id><pub-id pub-id-type="pmid">27653447</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Heller</surname><given-names>SR</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Perez</surname><given-names>AT</given-names></name><name><surname>Fleck</surname><given-names>PR</given-names></name><name><surname>Mehta</surname><given-names>CR</given-names></name><name><surname>Kupfer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Alogliptin after acute coronary syndrome in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1305889</pub-id><pub-id pub-id-type="pmid">23992602</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Hirshberg</surname><given-names>B</given-names></name><name><surname>Ohman</surname><given-names>P</given-names></name><name><surname>Frederich</surname><given-names>R</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Hoffman</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307684</pub-id><pub-id pub-id-type="pmid">23992601</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JB</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Engel</surname><given-names>SS</given-names></name><name><surname>Garg</surname><given-names>J</given-names></name><name><surname>Josse</surname><given-names>R</given-names></name><name><surname>Kaufman</surname><given-names>KD</given-names></name><name><surname>Koglin</surname><given-names>J</given-names></name><name><surname>Korn</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>3</issue><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1501352</pub-id><pub-id pub-id-type="pmid">26052984</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Menon</surname><given-names>V</given-names></name><name><surname>Perez</surname><given-names>AT</given-names></name><name><surname>Fleck</surname><given-names>PR</given-names></name><name><surname>Mehta</surname><given-names>CR</given-names></name><name><surname>Kupfer</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><etal/></person-group><article-title>Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9982</issue><fpage>2067</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)62225-X</pub-id><pub-id pub-id-type="pmid">25765696</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivertsen</surname><given-names>J</given-names></name><name><surname>Rosenmeier</surname><given-names>J</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Vilsboll</surname><given-names>T</given-names></name></person-group><article-title>The effect of glucagon-like peptide 1 on cardiovascular risk</article-title><source>Nat Rev Cardiol</source><year>2012</year><volume>9</volume><issue>4</issue><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2011.211</pub-id><pub-id pub-id-type="pmid">22290234</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Hopper</surname><given-names>I</given-names></name><name><surname>Skiba</surname><given-names>M</given-names></name><name><surname>Krum</surname><given-names>H</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants</article-title><source>Cardiovasc Ther</source><year>2014</year><volume>32</volume><issue>4</issue><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1111/1755-5922.12075</pub-id><pub-id pub-id-type="pmid">24750644</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>J</given-names></name><name><surname>Ishizu</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Kodama</surname><given-names>K</given-names></name><name><surname>Bando</surname><given-names>YK</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name><name><surname>Node</surname><given-names>K</given-names></name></person-group><article-title>Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study</article-title><source>Int J Cardiol</source><year>2014</year><volume>174</volume><issue>2</issue><fpage>383</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2014.03.204</pub-id><pub-id pub-id-type="pmid">24768387</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname><given-names>J</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name><name><surname>Kitakaze</surname><given-names>M</given-names></name><name><surname>Ishizu</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Kitagawa</surname><given-names>K</given-names></name><name><surname>Kamiya</surname><given-names>H</given-names></name><name><surname>Ajioka</surname><given-names>M</given-names></name><name><surname>Ishihara</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name><etal/></person-group><article-title>The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial</article-title><source>PLoS Med</source><year>2016</year><volume>13</volume><issue>6</issue><fpage>e1002051</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1002051</pub-id><pub-id pub-id-type="pmid">27351380</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>RM</given-names></name><name><surname>Bierig</surname><given-names>M</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Flachskampf</surname><given-names>FA</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Picard</surname><given-names>MH</given-names></name><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Seward</surname><given-names>J</given-names></name><name><surname>Shanewise</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Recommendations for chamber quantification: a report from the American Society of Echocardiography&#x02019;s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology</article-title><source>J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr</source><year>2005</year><volume>18</volume><issue>12</issue><fpage>1440</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1016/j.echo.2005.10.005</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Alonso</surname><given-names>DR</given-names></name><name><surname>Lutas</surname><given-names>EM</given-names></name><name><surname>Gottlieb</surname><given-names>GJ</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Sachs</surname><given-names>I</given-names></name><name><surname>Reichek</surname><given-names>N</given-names></name></person-group><article-title>Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings</article-title><source>Am J Cardiol</source><year>1986</year><volume>57</volume><issue>6</issue><fpage>450</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(86)90771-X</pub-id><pub-id pub-id-type="pmid">2936235</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>RM</given-names></name><name><surname>Bierig</surname><given-names>M</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Flachskampf</surname><given-names>FA</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Picard</surname><given-names>MH</given-names></name><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Seward</surname><given-names>J</given-names></name><name><surname>Shanewise</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Recommendations for chamber quantification: a report from the American Society of Echocardiography&#x02019;s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology</article-title><source>J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr</source><year>2005</year><volume>18</volume><issue>12</issue><fpage>1440</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1016/j.echo.2005.10.005</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015; 36(27):1718&#x02013;1727, 1727a&#x02013;1727c.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>From</surname><given-names>AM</given-names></name><name><surname>Scott</surname><given-names>CG</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name></person-group><article-title>Changes in diastolic dysfunction in diabetes mellitus over time</article-title><source>Am J Cardiol</source><year>2009</year><volume>103</volume><issue>10</issue><fpage>1463</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2009.01.358</pub-id><pub-id pub-id-type="pmid">19427447</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruhashi</surname><given-names>T</given-names></name><name><surname>Higashi</surname><given-names>Y</given-names></name><name><surname>Kihara</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Sata</surname><given-names>M</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name><name><surname>Odawara</surname><given-names>M</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>J</given-names></name><etal/></person-group><article-title>Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study</article-title><source>Cardiovasc Diabetol</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>134</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0438-x</pub-id><pub-id pub-id-type="pmid">27624168</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomiyama</surname><given-names>H</given-names></name><name><surname>Miwa</surname><given-names>T</given-names></name><name><surname>Kan</surname><given-names>K</given-names></name><name><surname>Matsuhisa</surname><given-names>M</given-names></name><name><surname>Kamiya</surname><given-names>H</given-names></name><name><surname>Nanasato</surname><given-names>M</given-names></name><name><surname>Kitano</surname><given-names>T</given-names></name><name><surname>Sano</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>J</given-names></name><name><surname>Iida</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study</article-title><source>Cardiovasc Diabetol</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>150</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0472-8</pub-id><pub-id pub-id-type="pmid">27809848</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Katakami</surname><given-names>N</given-names></name><name><surname>Shiraiwa</surname><given-names>T</given-names></name><name><surname>Yoshii</surname><given-names>H</given-names></name><name><surname>Onuma</surname><given-names>T</given-names></name><name><surname>Kuribayashi</surname><given-names>N</given-names></name><name><surname>Osonoi</surname><given-names>T</given-names></name><name><surname>Kaneto</surname><given-names>H</given-names></name><name><surname>Kosugi</surname><given-names>K</given-names></name><name><surname>Umayahara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial</article-title><source>Diabetes Care</source><year>2016</year><volume>39</volume><issue>3</issue><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.2337/dc15-2145</pub-id><pub-id pub-id-type="pmid">26822324</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Katakami</surname><given-names>N</given-names></name><name><surname>Yoshii</surname><given-names>H</given-names></name><name><surname>Onuma</surname><given-names>T</given-names></name><name><surname>Kaneto</surname><given-names>H</given-names></name><name><surname>Osonoi</surname><given-names>T</given-names></name><name><surname>Shiraiwa</surname><given-names>T</given-names></name><name><surname>Kosugi</surname><given-names>K</given-names></name><name><surname>Umayahara</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A)</article-title><source>Diabetes Care</source><year>2016</year><volume>39</volume><issue>1</issue><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.2337/dc15-0781</pub-id><pub-id pub-id-type="pmid">26628419</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontes-Carvalho</surname><given-names>R</given-names></name><name><surname>Ladeiras-Lopes</surname><given-names>R</given-names></name><name><surname>Bettencourt</surname><given-names>P</given-names></name><name><surname>Leite-Moreira</surname><given-names>A</given-names></name><name><surname>Azevedo</surname><given-names>A</given-names></name></person-group><article-title>Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s12933-014-0168-x</pub-id><pub-id pub-id-type="pmid">25582424</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugger</surname><given-names>H</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group><article-title>Molecular mechanisms of diabetic cardiomyopathy</article-title><source>Diabetologia</source><year>2014</year><volume>57</volume><issue>4</issue><fpage>660</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1007/s00125-014-3171-6</pub-id><pub-id pub-id-type="pmid">24477973</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes-Antras</surname><given-names>J</given-names></name><name><surname>Picatoste</surname><given-names>B</given-names></name><name><surname>Ramirez</surname><given-names>E</given-names></name><name><surname>Egido</surname><given-names>J</given-names></name><name><surname>Tunon</surname><given-names>J</given-names></name><name><surname>Lorenzo</surname><given-names>O</given-names></name></person-group><article-title>Targeting metabolic disturbance in the diabetic heart</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0173-8</pub-id><pub-id pub-id-type="pmid">25856422</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>dos Santos</surname><given-names>L</given-names></name><name><surname>Salles</surname><given-names>TA</given-names></name><name><surname>Arruda-Junior</surname><given-names>DF</given-names></name><name><surname>Campos</surname><given-names>LC</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>Barreto</surname><given-names>AL</given-names></name><name><surname>Antonio</surname><given-names>EL</given-names></name><name><surname>Mansur</surname><given-names>AJ</given-names></name><name><surname>Tucci</surname><given-names>PJ</given-names></name><name><surname>Krieger</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure</article-title><source>Circ Heart Fail</source><year>2013</year><volume>6</volume><issue>5</issue><fpage>1029</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.112.000057</pub-id><pub-id pub-id-type="pmid">23894014</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Almeida</surname><given-names>Salles T</given-names></name><name><surname>Zogbi</surname><given-names>C</given-names></name><name><surname>de Lima</surname><given-names>TM</given-names></name><name><surname>de Godoi</surname><given-names>Carneiro C</given-names></name><name><surname>Garcez</surname><given-names>AT</given-names></name><name><surname>Barbeiro</surname><given-names>HV</given-names></name><name><surname>Antonio</surname><given-names>EL</given-names></name><name><surname>Dos Santos</surname><given-names>L</given-names></name><name><surname>da Costa</surname><given-names>Pereira A</given-names></name><name><surname>Tucci</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>The contributions of dipeptidyl peptidase IV to inflammation in heart failure</article-title><source>Ame J Physiol Heart Circ Physiol</source><year>2016</year><volume>310</volume><issue>11</issue><fpage>H1760</fpage><lpage>H1772</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00735.2015</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigeta</surname><given-names>T</given-names></name><name><surname>Aoyama</surname><given-names>M</given-names></name><name><surname>Bando</surname><given-names>YK</given-names></name><name><surname>Monji</surname><given-names>A</given-names></name><name><surname>Mitsui</surname><given-names>T</given-names></name><name><surname>Takatsu</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>XW</given-names></name><name><surname>Okumura</surname><given-names>T</given-names></name><name><surname>Hirashiki</surname><given-names>A</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions</article-title><source>Circulation</source><year>2012</year><volume>126</volume><issue>15</issue><fpage>1838</fpage><lpage>1851</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.096479</pub-id><pub-id pub-id-type="pmid">23035207</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaruba</surname><given-names>MM</given-names></name><name><surname>Theiss</surname><given-names>HD</given-names></name><name><surname>Vallaster</surname><given-names>M</given-names></name><name><surname>Mehl</surname><given-names>U</given-names></name><name><surname>Brunner</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>R</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Krieg</surname><given-names>L</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>B</given-names></name><etal/></person-group><article-title>Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction</article-title><source>Cell Stem Cell</source><year>2009</year><volume>4</volume><issue>4</issue><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2009.02.013</pub-id><pub-id pub-id-type="pmid">19341621</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauve</surname><given-names>M</given-names></name><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Momen</surname><given-names>MA</given-names></name><name><surname>Zhou</surname><given-names>YQ</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><issue>4</issue><fpage>1063</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.2337/db09-0955</pub-id><pub-id pub-id-type="pmid">20097729</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Keyes</surname><given-names>KT</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Perez-Polo</surname><given-names>JR</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Birnbaum</surname><given-names>Y</given-names></name></person-group><article-title>The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2010</year><volume>298</volume><issue>5</issue><fpage>H1454</fpage><lpage>H1465</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00867.2009</pub-id><pub-id pub-id-type="pmid">20207816</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>HR</given-names></name><name><surname>Al Badarin</surname><given-names>FJ</given-names></name><name><surname>Al Shami</surname><given-names>HA</given-names></name><name><surname>Bhatti</surname><given-names>SK</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Bell</surname><given-names>DS</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>JH</given-names></name></person-group><article-title>Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus</article-title><source>Am J Cardiol</source><year>2012</year><volume>110</volume><issue>6</issue><fpage>826</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2012.04.061</pub-id><pub-id pub-id-type="pmid">22703861</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>LM</given-names></name><name><surname>Kydd</surname><given-names>AC</given-names></name><name><surname>Read</surname><given-names>PA</given-names></name><name><surname>Ring</surname><given-names>LS</given-names></name><name><surname>Bond</surname><given-names>SJ</given-names></name><name><surname>Hoole</surname><given-names>SP</given-names></name><name><surname>Dutka</surname><given-names>DP</given-names></name></person-group><article-title>Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease</article-title><source>Circ Cardiovasc Imaging</source><year>2014</year><volume>7</volume><issue>2</issue><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.113.000785</pub-id><pub-id pub-id-type="pmid">24503784</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G, Perticone F. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2016 Endocrine. 2016 Nov 9. [<bold>Epub ahead of print</bold>].</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oe</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Kihara</surname><given-names>H</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Miyoshi</surname><given-names>T</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>J</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group><article-title>Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0242-z</pub-id><pub-id pub-id-type="pmid">26084668</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogueira</surname><given-names>KC</given-names></name><name><surname>Furtado</surname><given-names>M</given-names></name><name><surname>Fukui</surname><given-names>RT</given-names></name><name><surname>Correia</surname><given-names>MR</given-names></name><name><surname>Dos Santos</surname><given-names>RF</given-names></name><name><surname>Andrade</surname><given-names>JL</given-names></name></person-group><article-title>Rossi da Silva ME: left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor&#x02014;a pilot study</article-title><source>Diabetol Metab Syndr</source><year>2014</year><volume>6</volume><issue>1</issue><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/1758-5996-6-103</pub-id><pub-id pub-id-type="pmid">25285158</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ussher</surname><given-names>JR</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Cardiovascular actions of incretin-based therapies</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><issue>11</issue><fpage>1788</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.301958</pub-id><pub-id pub-id-type="pmid">24855202</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saponaro</surname><given-names>F</given-names></name><name><surname>Sonaglioni</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Montefusco</surname><given-names>L</given-names></name><name><surname>Lombardo</surname><given-names>M</given-names></name><name><surname>Adda</surname><given-names>G</given-names></name><name><surname>Arosio</surname><given-names>M</given-names></name></person-group><article-title>Improved diastolic function in type 2 diabetes after a six month liraglutide treatment</article-title><source>Diabetes Res Clin Pract</source><year>2016</year><volume>118</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2016.04.046</pub-id><pub-id pub-id-type="pmid">27485853</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Vandvik</surname><given-names>PO</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Bala</surname><given-names>MM</given-names></name><name><surname>Sohani</surname><given-names>ZN</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies</article-title><source>BMJ (Clin Res ed)</source><year>2016</year><volume>352</volume><fpage>i610</fpage></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>MB</given-names></name><name><surname>Tudrej</surname><given-names>BV</given-names></name><name><surname>Soustre</surname><given-names>J</given-names></name><name><surname>Buisson</surname><given-names>M</given-names></name><name><surname>Archambault</surname><given-names>P</given-names></name><name><surname>Pouchain</surname><given-names>D</given-names></name><name><surname>Vaillant-Roussel</surname><given-names>H</given-names></name><name><surname>Gueyffier</surname><given-names>F</given-names></name><name><surname>Faillie</surname><given-names>JL</given-names></name><name><surname>Perault-Pochat</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials</article-title><source>Diabetes Metab</source><year>2017</year><volume>43</volume><issue>1</issue><fpage>48</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.diabet.2016.09.005</pub-id><pub-id pub-id-type="pmid">27745828</pub-id></element-citation></ref></ref-list></back></article>